SS-31 — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Mitochondria-targeted tetrapeptide
Reported half-life: Approximately 2–4 hours
Routes used in the literature: Subcutaneous and intravenous in the human trial programme
Also written as: Elamipretide

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Primary mitochondrial myopathy trials

Reported quantity: 5 mg subcutaneously
Frequency: Once daily
Study duration: 24–48 weeks in the registered programme

Six-minute walk distance was the primary endpoint in the pivotal studies.

Earlier dose-ranging arms

Reported quantity: 0.01–0.25 mg/kg/hour intravenously
Frequency: Continuous infusion in the earliest studies
Study duration: Hours to days

The subcutaneous 5 mg daily figure superseded the infusion designs.

Rodent cardiolipin and renal models

Reported quantity: 1–3 mg/kg
Frequency: Once or twice daily
Study duration: 1–6 weeks

Cardiolipin binding in the inner mitochondrial membrane is the proposed mechanism.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

SS-31 · 10 mg Vial

SS-31 is dosed at 5 mg–10 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 10 mg/mL. This information is for research and educational use only.

Reconstitute: Add 1.0 mL bacteriostatic water → 10 mg/mL concentration for single‑syringe convenience.
Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Standard / Gradual Approach (1 mL = 10 mg/mL)

Week	Daily Dose (mg)	Units (per injection) (mL)
Weeks 1–2	5 mg (5000 mcg)	50 units (0.50 mL)
Weeks 3–8	10 mg (10,000 mcg)	100 units (1.0 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size SS-31 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

SS-31 · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	5 mg =	10 mg =
10 mg	3.33 mg/ml	33 mcg	150 units	300 units
30 mg	10.00 mg/ml	100 mcg	50 units	100 units
50 mg	16.67 mg/ml	167 mcg	30 units	60 units

Unit columns use the range reported for this compound (5 mg–10 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 50 mg vial in 2 mL of bacteriostatic water gives 25 mg/mL.

Open the reconstitution calculator

How to read these figures

Injection-site reactions were the most commonly reported finding across the trial programme.
Several of the registered trials did not meet their primary endpoints — read outcomes, not just protocols.
SS-31 and elamipretide are the same molecule under research and development names.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome
Reid Thompson W, Hornby B, Manuel R, et al. · Genet Med · 2021 · PMID 33077895
Patients with Barth syndrome received daily subcutaneous elamipretide (SS-31) injections at a fixed dose in a randomized placebo-controlled trial followed by open-label extension.
View the record
[2]
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Karaa A, Haas R, Goldstein A, et al. · Neurology · 2018 · PMID 29491012
Adults with primary mitochondrial myopathy received ascending subcutaneous doses of elamipretide (SS-31) over a dose-escalation protocol to assess safety and pharmacodynamics.
View the record
[3]
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy
Bhatti JS, et al. (crossover trial authors) · J Cachexia Sarcopenia Muscle · 2020 · DOI 10.1002/jcsm.12559
Crossover trial in adults with mitochondrial myopathy comparing daily subcutaneous elamipretide dosing against placebo over defined treatment periods.
View the record

Search the databases yourself

Read the SS-31 research brief

Other performance compounds

5-Amino-1MQSmall-molecule NNMT inhibitor ACE-031Soluble activin receptor type IIB fused to an IgG1 Fc domain (myostatin trap)DermorphinHeptapeptide opioid agonist originally isolated from Phyllomedusa frog skin

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.